Acute Labetalol Use in Preeclampsia

• Status: Terminated
• Trial end date: 2020-07-20
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albany Medical College
• Treatments: Labetalol

Criteria

Inclusion Criteria:

• BMI ≥ 30

• Age ≥ 18 years

• Gestational age ≥ 24 weeks

• Singleton gestation

• One sustained severe range blood pressure at Albany Medical Center

Exclusion Criteria:

• Known allergic reaction to labetlol

• Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month)

• Obstructive airway disease

• Bradycardia < 70 beats/min

• Heart block > 1st degree or history of heart failure